This site is intended for healthcare professionals only

HIV drug could prevent skin cancer becoming untreatable

Written by: | Published:

Melanomas can quickly become resistant to treatmen Melanomas can quickly become resistant to treatment

A drug used to treat HIV could stop changes in skin cancer cells that leads to them becoming resistant to treatment, according to a study published in Cancer Cell.

The researchers, from the University of Manchester, looked at melanoma skin cancers from 11 patients who had started standard treatment for the cancer. They found that the cancer cells are able to withstand the standard drugs in the first two weeks of treatment, by using a ‘molecular switch.’ The cells then went on to develop permanent resistance through these genetic changes.

‘In the first few weeks of standard treatment for skin cancer, the cancer cells become stronger and more robust against treatment,’ said Professor Claudia Wellbrock, lead author of the study. ‘But if we can target skin cancer cells before they become fully resistant, we would have a much better chance of blocking their escape.’

The HIV drug, called nelfinavir, works by blocking the molecular switch which leads to the genetic changes. The researchers discovered that nelfinavir can make standard skin cancer treatments more potent and delay drug resistance, making available treatments effective for a longer period of time.

‘Melanoma can be difficult to treat because the cancer becomes resistant to drugs quite quickly. But this exciting research means we might be able to fight back by blocking the first steps towards resistance, so that treatments are effective for longer,’ said professor Nic Jones, director of Cancer Research UK’s Manchester Cancer Research Centre.

‘While drug resistance is a big challenge, we’re making great progress. Drug resistance in late stage skin cancer is still a big problem and something we need to tackle. We’ve seen big steps forward recently with the development of immunotherapies but this approach could stop skin cancer developing resistance at an earlier point,’ he added.

What do you think? Leave a comment below or tweet your views to @IndyNurseMag

This material is protected by MA Healthcare Ltd copyright.
See Terms and Conditions.


Verá good
Posted by: ,

Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code

Read a free issue from Practice Nursing

Register to read a free issue from our sister publication, Practice Nursing.

Including articles on asthma, diabetes and more. Read your copy.


Sign up to the newsletter


Independent Nurse is the professional resource for primary care and community nurses, providing clinical articles for practice nurses and prescribers.


Subscribe to our newsletter and stay up to date with the latest nursing news.

Stay Connected

Stay social with Independent Nurse by following us on Twitter, liking us on Facebook or connecting on LinkedIn.


Need access to some of our older articles? You can view our archive, or alternatively contact us.

Contact Us

MA Healthcare Ltd.
St Jude's Church, Dulwich Road
London, SE24 0PB

Tel: +44 (0)20 7738 5454
Registered in England and Wales No. 01878373

Meet the team


Find out how to contribute to Independent Nurse here.